Olivia R. King

Associate

Overview

Olivia King is an associate with Foley & Lardner LLP and a member of the firm’s Health Care Industry Team.

Olivia was selected for the inaugural Mayo-Foley Health Law Fellowship, consisting of summer internships with the Mayo Clinic Legal Department in Rochester, Minnesota (2017) and Foley (2018). While at the Mayo Clinic, Olivia researched and prepared memorandum on state and federal medical prescribing and licensure requirements with analysis of potential implications on telemedicine initiatives and state mental health ombudsman reporting. In addition, she researched federal and state regulations regarding FDA medical device guidance, scope of practice, fraud and abuse and accreditation issues. Olivia also presented at the Legal Department annual meeting on appropriate utilization of paralegal staff and unauthorized practice of law.

"Foley is the premier firm for telehealth counsel."
"A market leader in telemedicine issues." "This is the Dream Team."
     - Chambers USA: America's Leading Business Lawyers (2020, 2021)

Prior to joining Foley, Olivia worked as a research assistant for the National Marrow Donor Program (NMDP), Be the Match, in the payer policy and legislative relations departments. In this role, Olivia researched and drafted a publication abstract on state disparities in Medicaid coverage of bone marrow transplants, in order to illustrate the importance of access to transplants. Olivia also researched and coauthored a white paper on care coordination efforts in bone marrow transplantation. Prior to her full time employment with NMDP, Olivia served as an intern with the organization where she assisted with advocacy efforts surrounding federal reauthorization legislation, and researched health insurance network adequacy standards surrounding bone marrow transplantation.

Representative Matters

  • Advised various telehealth companies on navigating federal and state changes in provider licensure and telehealth modalities during the COVID-19 public health emergency. The work allowed the companies to immediately take action and expand their platforms to provide services across multiple states.

Publications

  • Co-author, “A Target on Telehealth: Government Action Against Telehealth Fraud in the Wake of COVID-19,” American Health Law Association (July 14, 2021)
  • Co-author, “Supreme Court Declines to Resolve Circuit Split on FCA “Objective Falsity” Issue,” Health Care Law Today (February 23, 2021)
  • Co-author, “D.C. Circuit Upholds Hospital Price Transparency: Regulations Paving Way for January 1, 2021 Effectiveness,” Health Care Law Today (January 13, 2021)
  • Co-author, “Challenging Physician Judgment: Is Your Institution Exposed to False Claims Act Liability?,” Health Care Law Today (December 10, 2020)
  • Co-author, “Protecting Your Institution from False Claims Act Allegations After Receipt of CARES Act Funding,” American Health Law Association (November 11, 2020)
  • Co-author, “Provider Relief Fund: Protecting Your Institution from False Claims Act Allegations after Receipt of CARES Act Funding,” Coronavirus Resource Center: Back to Business (July 6, 2020)
  • Co-author, “Trends in State COVID-19 Liability Waivers For Care Centers,” Law360 (June 16, 2020)
  • Co-author, “COVID-19: CMS Issues FAQ Regarding Emergency Medical Treatment and Labor Act,” Coronavirus Resource Center: Back to Business (May 7, 2020)
  • Co-author, “COVID-19: States Protect Long-Term Care Facilities from Liability,” Coronavirus Resource Center: Back to Business (May 1, 2020)
  • Co-author, “COVID-19: CMS Issues Telehealth Guidance for State Medicaid and CHIP Programs,” Coronavirus Resource Center: Back to Business (April 28, 2020)
  • Co-author, “COVID-19: FDA Issues Guidance for Ventilator and Respirator Manufacturers,” Coronavirus Resource Center: Back to Business (March 26, 2020)
  • Co-author, “COVID-19: CMS Issues EMTALA Guidance,” Coronavirus Resource Center: Back to Business (March 17, 2020)
  • Co-author, “Behavioral Health & Substance Abuse Services: Massachusetts Proposal Reflects Focus on Expanding Access and Coverage,” Health Care Law Today (January 22, 2020)
  • Co-author, “Organ Procurement Organizations: CMS Proposes Revisions to Conditions For Coverage Designed To Increase Donated Organs,” Health Care Law Today (January 6, 2020)
  • Co-author, “Impossible or Laudable: The Proposed Massachusetts Primary and Behavioral Health Care Spending Requirement,” Health Care Law Today (December 17, 2019)
  • Co-author, “Massachusetts Governor Proposes Facility Fee Ban,” Health Care Law Today (December 12, 2019)
  • Co-author, “Oncology Care First: What You Need to Know About the Proposed Oncology Care First Model,” Health Care Law Today (November 18, 2019)
  • Co-author, “Promoting Interoperability: Changes to the CMS EHR Incentive Program,” Digital Health Legal (August 2018)
  • Co-author, “Patient Centered Care Coordination in Hematopoietic Cell Transplantation,” American Society of Hematology Blood Advances (July 19, 2017)

Education

  • Boston University School of Public Health (M.P.H., 2020)
  • Boston University School of Law (J.D., cum laude, 2019)
    • Concentration in Health Law with Honors
    • Paul J. Liacos Distinguished Scholar
    • Dean’s Award for Health Law
    • Symposium editor, American Journal of Law and Medicine
    • Networking director, Health Law Association
  • University of Michigan (B.A., 2015)
    • Distinction in Political Science
    • University Honors
    • James B. Angell Scholar

Admissions

  • Massachusetts